MedTrace Logo

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

NCT02786732 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-06-01

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

210mg Brodalumab

Brodalumab 210mg administered subcutaneously

BIOLOGICAL

140mg Brodalumab

Brodalumab 140mg administered subcutaneously

BIOLOGICAL

Ustekinumab

Ustekinumab 45mg or 90mg adminstered subcutaneously

BIOLOGICAL

Placebo

Placebo administered subcutaneously

Sponsors & Collaborators

  • MedDerm Associates

    lead INDUSTRY

Principal Investigators

  • Michelle T Pelle, M.D. · MedDerm Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-06-30
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786732 on ClinicalTrials.gov